Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Dec 22, 2022 (4 years ago)

Tacrolimus 0.03% Oph Solution Tacrolimus 0.1%

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

TACROLIMUS 0.03% OPH SOLUTION TACROLIMUS 0.1% (1ML DROPTAINER) OPH SOLUTION TACROLIMUS -CORN OIL- 0.03% OPH SOLUTION TACROLIMUS-VET- 0.02% (10ML DROPPER) OPHTHALMIC TACROLIMUS-VET- 0.02% (15ML DROPPER) OPHTHALMIC TACROLIMUS-VET- 0.02% (5ML DROPPER) OPHTHALMIC TACROLIMUS-VET- 0.03% (10ML DROPPER) OPHTHALMIC, Rx Only, Pharmacy Innovations, 2936 W 17th St., Erie, PA.

Drug: Tacrolimus Category: Eye Drops & Ophthalmic

Recalling firm
Pharmacy Innovations
Origin
PA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0237-2023 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Tacrolimus recalls

See all
Class I · High risk

Prograf (tacrolimus)

Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules

Ongoing Failed specification Astellas Pharma US Inc. NDC 0469-0607-73 D-0211-2025
Class I · High risk

Astagraf XL

Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules

Ongoing Failed specification Astellas Pharma US Inc. NDC 0469-0647-73 D-0210-2025
Class II · Moderate risk

Tacrolimus Capsules

Presence of Foreign Tablets/Capsules: One 0.5 mg Tacrolimus capsule found in a bottle of 1 mg Tacrolimus capsules.

Terminated Particulate / foreign matter Dr. Reddy's Laboratories, Inc. NDC 55111-526-01 D-0219-2024
Class II · Moderate risk

Tacrolimus Capsules

Presence of Foreign Tablets/Capsules: Presence of one Tacrolimus 1 mg capsule co-mingled in a bottle containing and labeled as Tacrolimus 0.5 mg capsules.

Ongoing Particulate / foreign matter Dr. Reddy's Laboratories, Inc. NDC 55111-525-01 D-0330-2023
Class III · Low risk

Tacrolimus Ointment

Defective Container: Tube split from side seam

Ongoing Packaging defect Glenmark Pharmaceuticals Inc., USA NDC 68462-534-35 D-1304-2022

Other recalls by Pharmacy Innovations

All 2022 recalls
Class II · Moderate risk

Voriconazole 10mg/Ml

Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.

Terminated Sterility / contamination Pharmacy Innovations D-0243-2023